Search Results
Aug 04, 2026, 16:05 ET Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
dabogratinib is currently advancing in three Phase 2 clinical trials for LG-UTUC (SURF303), IR NMIBC (SURF302), and ACH (BEACH301). The FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to oral dabogratinib for the treatment of achondroplasia.Please visit the
More news about: Tyra Biosciences
Aug 04, 2026, 16:05 ET TransMedics Reports Second Quarter 2026 Financial Results
our OCS products in the United States, the European Union and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration (the "FDA") or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including
More news about: TransMedics Group, Inc.
Aug 04, 2026, 16:05 ET Qualys Announces Second Quarter 2026 Financial Results
2025.Second Quarter 2026 Business HighlightsQualys' TotalCloud solution achieved FedRAMP High Authorization, sponsored by the U.S. Drug Enforcement Administration (DEA). This extends the Qualys Government Platform's authorization to include Cloud-Native Application Protection Platform
More news about: Qualys, Inc.
Aug 04, 2026, 16:01 ET Rigel Reports Second Quarter 2026 Financial Results
olutasidenib in Japan and delivery of drug supplies; $5.0 million of revenue from Grifols S.A. (Grifols) related to earned royalties and delivery of drug supplies; and $0.3 million of revenue from Medison Pharma (Medison) related to earned royalties and delivery of drug supplies. Contract revenues from collaborations
More news about: Rigel Pharmaceuticals, Inc.
Aug 04, 2026, 16:01 ET Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
directed against HPV 6 and HPV 11 proteins in patients with recurrent respiratory papillomatosis (RRP). PAPZIMEOS has been approved by the US Food and Drug Administration (FDA) for the treatment of adults with RRP.Broad US adoption: Well over 500 patients have registered through
More news about: Precigen, Inc.
Aug 04, 2026, 16:01 ET AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
collaboration with Xencor, Inc.YL201 is an investigational B7-H3 targeting antibody-drug conjugate being developed by MediLink.Zocilurtatug pelitecan is an investigational DLL3 targeting antibody-drug conjugate being developed by Zai Lab Limited.Etakafusp alfa (AB248) is
More news about: Amgen
Aug 04, 2026, 15:28 ET Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
and SAN DIEGO, Calif., Aug. 4, 2026 /PRNewswire/ -- Lunai Bioworks Inc. (Nasdaq: LNAI), a biology-first AI drug discovery company, today announced the execution of a Master Collaboration Agreement with BrainStorm Therapeutics Inc. ("BrainStorm"), an AI-powered
More news about: Lunai Bioworks Inc.
Aug 04, 2026, 14:52 ET America's 9-to-1 Health Spending Gap With Mexico Explains Lower Rehab Costs, TranquilHearts New Analysis Finds
$5,000 to $80,000 depending on the facility (National Center for Drug Abuse Statistics, 2024). At the premium end of the market, a month at a U.S. luxury rehab facility typically costs
More news about: TranquilHearts Private Luxury Rehab and Addiction Treatment Mexico
Aug 04, 2026, 12:00 ET Phylo and Chugai partner to advance AI agents in drug discovery
tools designed for the unique challenges of drug discovery research and capable of connecting insights across diverse sources of knowledge. We believe Biomni Lab can help our scientists explore scientific questions more effectively and accelerate our drug discovery to create innovative medicines for
More news about: Phylo, Inc.
Aug 04, 2026, 11:09 ET Disposable Syringes Market: USD 24.94 Billion by 2031 as Safety-Engineered Devices & Rising Injection Volumes Accelerate Market Expansion, Says Mordor Intelligence
adoption of injectable therapies. The market continues to expand as healthcare providers prioritize infection prevention, injection safety, and efficient drug-delivery solutions across hospitals, clinics, diagnostic centers, and home healthcare settings.
More news about: Mordor Intelligence Private Limited
Aug 04, 2026, 10:31 ET Lumbar Disc Herniation Market is Projected to Reach USD 7.2 Billion by 2036 as Novel Therapies and Minimally Invasive Treatments are Gaining Momentum | DelveInsight
addressing the underlying disc degeneration. Condoliase (SI-6603), developed by Seikagaku Corporation, is currently the only approved drug specifically indicated for LDH. Approved in Japan, it is administered as a single intradiscal injection that lowers intradiscal pressure by selectively
More news about: DelveInsight Business Research, LLP
Aug 04, 2026, 10:30 ET Research Use Recombinant Protein Market worth USD 1.55 billion by 2031 - Exclusive Report by MarketsandMarkets™
studies.Pharmaceutical & Biotechnology Companies accounted for the largest end-user share in 2025, fueled by increasing R&D investments and expanding drug discovery pipelines.Thermo Fisher Scientific Inc. (US), Bio-Techne (US), and Merck KGaA (Germany) emerged as the leading market players based
More news about: MarketsandMarkets
Aug 04, 2026, 10:03 ET A New PBM Contract Does Not Guarantee Better Results, SHARx Explains Why
the arrangement, who determines where members are allowed to fill specialty medication, and whether the vendor benefits when prescription volume or drug spending increases.That review should extend beyond the PBM named in the proposal. Employers should understand the roles of affiliated specialty
More news about: SHARx
Aug 04, 2026, 10:00 ET Q2BI Expands Asia-Pacific Footprint with New Offices in Taipei, Kuala Lumpur, and Melbourne
from first-in-human studies through FDA submissions.Since its founding, Q2BI has contributed to more than 1,800 clinical studies and over 50 New Drug Application (NDA) and Biologics License Application (BLA) approvals worldwide. Its teams have supported clinical programs across a broad range of therapeutic
More news about: Q-Square Business Intelligence (Q2BI)
Aug 04, 2026, 10:00 ET NIPRO Launches Expanded Hemodialysis with ELISIO™-HX to U.S. Providers Following FDA Clearance
U.S. commercial launch of ELISIO-HX, a medium-cutoff dialyzer featuring super high-flux membrane technology. Enabled by the recent U.S. Food and Drug Administration (FDA) 510(k) clearance of ELISIO-HX, NIPRO is introducing its expanded hemodialysis approach with a super high-flux membrane, or HDs
More news about: Nipro Medical Corporation
Aug 04, 2026, 08:30 ET Accelerate Translational Research with Quantitative Image Analysis, Upcoming Webinar Hosted by Xtalks
standardized methods and quality control improve the reproducibility of imaging results, strengthen human dose estimation and support greater confidence in drug development decisions.TORONTO, Aug. 4, 2026 /PRNewswire/ -- Preclinical
More news about: Xtalks
Aug 04, 2026, 08:30 ET AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth
investment aligns with Asymchem Group's differentiated, one-stop, end-to-end CDMO strategy.Globally, pipelines involving antibody-drug conjugates (ADCs), novel drug conjugates (NDCs), and bispecific and multispecific antibodies are advancing rapidly into clinical development. At the same time, outsourcing
More news about: AsymBio
Aug 04, 2026, 08:30 ET Prevent Pharmacy Copay Misuse Before It Erodes Millions in GTN, Upcoming Webinar Hosted by Xtalks
customers. Founded in 2020 and headquartered in Irvine, California, RIS Rx serves leading pharmaceutical manufacturers across a growing portfolio of drug brands.Learn more at
More news about: Xtalks
Aug 04, 2026, 08:21 ET FDA Grants Fast Track Designation to Xellsmart Off-The-Shelf Cell Therapy for Parkinson's Disease
Parkinson's disease—the world's second most prevalent neurodegenerative disorder — has been officially awarded Fast Track Designation (FTD) by the US Food and Drug Administration (FDA). This regulatory designation underscores the US health authority's recognition of XS411's clinical value and potential to address
More news about: XellSmart Biopharmaceutical Co., Ltd.
Aug 04, 2026, 08:15 ET Psilera Announces Fall Conference Schedule to Showcase Next-Generation Psychedelic and Neuroplastogen Pipeline
Fall Conference Schedule9th Annual Neuropsychiatric Drug Development Summit September 15 - 17, Boston, MAMagali Haas, MD-PhD, Chief Medical Officer, will participate
More news about: Psilera Inc.
Aug 04, 2026, 08:01 ET Pharmacy System Rewards the Wrong Results. It is Working as Designed
result."When Revenue Grows as Drug Spending RisesNational prescription drug spending increased 7.9% to $467 billion in 2024 after growing 10.8% the previous year, according to the Centers for Medicare & Medicaid Services (CMS). Retail prescription drug spending is also projected by the
More news about: SHARx
Aug 04, 2026, 08:00 ET Acosta Opens New Growth Channel for Manufacturers Through Salvatori-Scott Partnership
Aug. 4, 2026 /PRNewswire/ -- As health and wellness brands look beyond traditional retail for growth, the independent drug channel is emerging as an increasingly important opportunity. To help manufacturers capitalize on that shift,
More news about: Acosta
Aug 04, 2026, 08:00 ET Xtalks Announces its Life Science Webinar Calendar for August 2026
Upcoming free, educational webinars from Xtalks will feature topics on clinical trials, patient recruitment and retention, drug safety, laboratory technologies, pharmaceutical manufacturing and supply chain, commercialization and HEOR and preclinical research.TORONTO,
More news about: Xtalks
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation,
More news about: Nuvation Bio Inc.
Aug 04, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete Activation System with 5-11× More Usable B1 Plus the Cofactors That Unlock It
amazon.com/dp/B0G66V5VV9.Pharmacokinetic research published in the European Journal of Drug Metabolism and Pharmacokinetics demonstrates that benfotiamine achieves plasma thiamine bioavailability of 1,147% compared to standard thiamine
More news about: Triquetra Health LLC